Cardiovascular outcomes trial data from EMPA-REG OUTCOME, CAROLINA and CARMELINA: Assessment of a novel staging system for type 2 diabetes.
Moahad S DarChristoph WannerNikolaus MarxAnne Pernille OfstadMichaela MattheusStefan KaspersSami A BégPublished in: Diabetes, obesity & metabolism (2023)
Applying the DSS across T2D clinical trial populations with different CV risk revealed a significantly increased risk of ACM and CV death with higher DSS stage. The DSS may merit assessment in other T2D populations and evaluation of the impact of additional outcomes, such as heart failure, could also be worthwhile.